Telangana: Gland Pharma has appointed Satnam Singh Loomba as Chief Operating Officer (COO); a Senior Management Personnel of the Company, effective May 01, 2024.
"We would like to inform you that upon the recommendation of the Nomination and Remuneration Committee, the Board of Directors of Gland Pharma Limited at its Meeting held today, i.e., Monday, April 29, 2024 has inter-alia considered and approved the appointment of Mr. Satnam Singh Loomba as Chief Operating Officer (COO) and Senior Management Personnel of the Company with effect from May 01, 2024," the Company stated in a BSE filing.
Satnam Singh Loomba is a senior pharmaceutical and management professional with an extensive background in multi-cultural, global environments for pharmaceutical Operations & Business and proficient in several multifunctional departments.
He has over 30 years of experience in API Operations & Development, Global Supply Planning & Operations in Manufacturing, Formulations, Global Material Sourcing, Corporate Strategic Business Planning, and Global Supply Chain for Global Markets. He has experience in managing operations in Formulations in Pharmaceuticals, Narcotics, Cosmetics, Food and Alternate medicine like Sterile Injectables, Infusions, Aerosol based Inhalers, Sprays, Lyophilized products, Insulin, Lozenges, etc. He has been instrumental in attaining accreditations from USFDA, MHRA, EDQM Cofepris, TGA, MCC, Health Canada, ANVISA, PMDA, KFDA.
Before joining Gland, Satnam was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
Loomba has done his Master of Business Administration from University Business School, Chandigarh. He is also a graduate in Chemical Engineering from Andhra University, Visakhapatnam.
Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It operates primarily under a business-to-business (B2B) model and has an excellent track record in developing, manufacturing, and marketing sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.